Compare · CDIO vs ORKA
CDIO vs ORKA
Side-by-side comparison of Cardio Diagnostics Holdings Inc. (CDIO) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDIO and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.74B, about 1192.6x CDIO ($5.7M).
- ORKA has been more active in the news (11 items in the past 4 weeks vs 6 for CDIO).
- ORKA has more recent analyst coverage (11 ratings vs 0 for CDIO).
- Company
- Cardio Diagnostics Holdings Inc.
- Oruka Therapeutics Inc.
- Price
- -
- -
- Market cap
- $5.7M
- $6.74B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 6
- 11
- Recent ratings
- 0
- 11
Latest CDIO
- Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City
- SEC Form 10-Q filed by Cardio Diagnostics Holdings Inc.
- SEC Form DEFA14A filed by Cardio Diagnostics Holdings Inc.
- SEC Form DEF 14A filed by Cardio Diagnostics Holdings Inc.
- Cardio Diagnostics Holdings, Inc. to Host Investor Call on Thursday, August 20, 2026
- SEC Form PRE 14A filed by Cardio Diagnostics Holdings Inc.
- SEC Form 4 filed by Director Fung Peter K
- SEC Form 4 filed by Director Betts Wendy J
- SEC Form 4 filed by Director Intrater James
Latest ORKA
- Chief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Edwards Larry Todd
- Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $782,882 worth of shares (7,000 units at $111.84) as part of a pre-agreed trading plan (SEC Form 4)
- General Counsel Quinlan Paul T exercised 52,000 shares at a strike of $11.60 and sold $5,641,409 worth of shares (52,000 units at $108.49) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,066,572 worth of shares (10,000 units at $106.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Oruka Therapeutics Inc.
- Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update